Mild cognitive impairment (MCI) is considered the intermediate stage between the changes observed in physiological aging and dementia. Currently, there is no drug therapy, and available drugs offer only minimal benefit on symptoms, only partially slowing the course of the condition. Studies in the literature have investigated the role of omega-3 fatty acids in MCI, and when administered over a period of six months, they appear to improve clinical condition and mood. In addition, medium-chain triglycerides (MCTs) appear to exert an antioxidant function, enhance cognitive ability in patients with MCI or Alzheimer's, and promote deep sleep state.
Age between 18 and 85 years;
Diagnosis of MCI;
Disease duration of less than 24 months from symptom onset;
Absence of malnutrition (diagnosed according to the NRS 2002 screening test) and with oral intakes sufficient to cover energy requirements (calculated by the Harris-Benedict formula, adjusted for activity factor and pathology);
Patients on total or supplemental enteral nutrition
Severe dysphagia
Patients with glycated hemoglobin > 8%
Patients on insulin therapy
Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Lead sponsor
Dr. Schär AG / SPA
Collaborator